Summary
Gilead Sciences, Inc. reported strong financial performance for the fiscal year ending December 31, 2010, with total revenues reaching $7.95 billion, a 14% increase year-over-year. This growth was primarily driven by its antiviral franchise, particularly Atripla and Truvada, which together accounted for 70% of total revenues. The company also saw significant contributions from its cardiovascular products, Letairis and Ranexa, and its newest respiratory product, Cayston, which demonstrated continued revenue growth. Gilead Sciences is actively managing its product pipeline through internal development and strategic acquisitions, with a notable focus on advancing its HIV and Hepatitis C drug candidates. The company's financial health is robust, supported by substantial operating cash flow and a significant cash balance. Gilead is also committed to returning value to shareholders through ongoing stock repurchase programs. However, investors should be aware of the company's reliance on its HIV products and the increasing competition in the HIV market, including the potential impact of generic drug introductions. Furthermore, changes in healthcare reform legislation in the U.S., potential pricing and reimbursement pressures in international markets, and ongoing patent litigation represent key risk factors that could impact future financial results.
Financial Highlights
52 data points| Revenue | $7.95B |
| Cost of Revenue | $1.87B |
| Gross Profit | $6.08B |
| SG&A Expenses | $1.04B |
| Operating Expenses | $3.99B |
| Operating Income | $3.96B |
| Interest Expense | $108.96M |
| Net Income | $2.90B |
| EPS (Basic) | $1.69 |
| EPS (Diluted) | $1.66 |
| Shares Outstanding (Basic) | 1.71B |
| Shares Outstanding (Diluted) | 1.75B |
Key Highlights
- 1Total revenues increased by 14% to $7.95 billion in 2010, driven by strong performance in antiviral products, particularly Atripla and Truvada.
- 2Atripla and Truvada sales combined represented 70% of total revenues, underscoring the company's reliance on its HIV franchise.
- 3Significant growth was observed in cardiovascular products (Letairis and Ranexa) and the newly launched Cayston.
- 4Research and development expenses increased by 14% to $1.07 billion, reflecting continued investment in pipeline development, especially in HIV and Hepatitis C.
- 5The company completed several strategic acquisitions in 2010 and early 2011 to bolster its product pipeline in inflammatory diseases, fibrotic diseases, and cancer.
- 6Gilead's financial position remains strong, with cash, cash equivalents, and marketable securities totaling $5.32 billion at year-end 2010.
- 7The company continued its substantial share repurchase program, repurchasing $4.02 billion of common stock in 2010 and authorizing an additional $5 billion program.